Kimiaki Utsugisawa

Hanamaki, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 80 publications

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

Journal: JAMA neurology

Published: August 10, 2026

Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.

Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.

Journal: Neurology. Clinical practice

Published: July 09, 2026

Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+).

Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+).

Journal: Frontiers in neurology

Published: May 08, 2026

Extrathymic malignancies in patients with myasthenia gravis: A Japanese multicenter study.

Extrathymic malignancies in patients with myasthenia gravis: A Japanese multicenter study.

Journal: Internal medicine (Tokyo, Japan)

Published: March 26, 2026

Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.

Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.

Journal: Therapeutic advances in neurological disorders

Published: December 24, 2025

Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study.

Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study.

Journal: Journal of neurology

Published: July 22, 2025

Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse®) in Japanese Patients with Lambert-Eaton Myasthenic Syndrome (LMS-005 Study).

Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse®) in Japanese Patients with Lambert-Eaton Myasthenic Syndrome (LMS-005 Study).

Journal: Internal medicine (Tokyo, Japan)

Published: June 18, 2025

Association between Myasthenia Gravis and Smoking.

Association between Myasthenia Gravis and Smoking.

Journal: Internal medicine (Tokyo, Japan)

Published: June 11, 2025

Corticosteroid-induced Cushingoid Appearance in Myasthenia Gravis.

Corticosteroid-induced Cushingoid Appearance in Myasthenia Gravis.

Journal: Internal medicine (Tokyo, Japan)

Published: June 04, 2025

Elucidating genetic backgrounds of myasthenia gravis in Japanese by genome-wide association studies and multi-omics analyses of thymoma.

Elucidating genetic backgrounds of myasthenia gravis in Japanese by genome-wide association studies and multi-omics analyses of thymoma.

Journal: Nature communications

Published: May 28, 2025

A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.

A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.

Journal: The New England journal of medicine

Published: April 09, 2025

Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension.

Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension.

Journal: Journal of neuromuscular diseases

Published: March 04, 2025

Showing 1-12 of 80

Last Updated: 09/26/2026